Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Functional food comment extension

This article was originally published in The Tan Sheet

Executive Summary

FDA announces in a Federal Register notice slated for publication Jan. 8 it will extend the comment period on conventional foods marketed as functional foods to March 5. The agency says each request it received "conveyed concern" the current 72-day comment period - closing 30 days after the Dec. 5 public hearing - does not allow sufficient time to "develop a meaningful or thoughtful response to the request for comments on the issues and questions" presented in an Oct. 25 notice on the topic. FDA announced in October 2006 it would hold a meeting to discuss the regulatory framework for products marketed as functional foods (1"The Tan Sheet" Oct. 30, 2006, p. 3). At its Dec. 5 meeting FDA heard comments from trade associations such as the Natural Products Association and the Council for Responsible Nutrition (2"The Tan Sheet" Dec. 11, 2006, p. 3)...

You may also be interested in...

Functional Foods, Supplements Need Level Regulatory Playing Field – Experts

A future guidance for industry is warranted on how food GMPs and dietary supplement GMPs will relate to functional food manufacturing, Natural Products Association VP-Scientific Affairs Daniel Fabricant, PhD, told FDA at a recent public hearing on the regulation of functional foods

FDA Public Meeting Will Explore Regulatory Options For Functional Foods

A distinct regulatory scheme for "functional foods" could benefit both industry and consumers, according to some analysts

Ambitious Amryt To File Butterfly Skin Drug Imminently

The Dublin-based drugmaker, powered by climbing revenues of Lojuxta and Myalept, is preparing its launch teams for Filsuvez, which has the potential to become the first treatment approved for epidermolysis bullosa and the company is banking on speedy regulatory reviews.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts